Vedana Therapeutics emerged from stealth last week with $46M to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
A New Westlake-Backed Biotech Takes Aim at Migraines
Share:
Vedana Therapeutics emerged from stealth last week with $46M to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.